Activated human T cell

Activated human T cells represent a functional state of T-lymphocytes that have transitioned from a quiescent, naive state to an active, proliferative state following the recognition of a specific antigen. This activation process is initiated when the T-cell receptor (TCR) recognizes a peptide-MHC complex on an antigen-presenting cell, a process that typically requires secondary co-stimulatory signals such as the interaction between CD28 and B7 molecules (Janeway et al., 2001). Once activated, these cells undergo rapid clonal expansion and differentiate into effector subtypes, such as helper (CD4+) or cytotoxic (CD8+) T cells, which secrete cytokines and execute immune functions to eliminate pathogens or abnormal cells (NIH, 2022). In clinical pharmacology, activated T cells are the primary drivers of transplant rejection and various autoimmune diseases, making them the central focus of immunosuppressive therapies designed to dampen their activity (StatPearls, 2023). Conversely, in the field of oncology, modern immunotherapies like checkpoint inhibitors and CAR-T cell therapies aim to specifically activate or redirect these cells to overcome tumor-induced immune evasion and enhance anti-tumor responses (Nature Reviews Cancer, 2018).

Other names

Activated T-lymphocyteEffector T cellBlastic T cellAntigen-activated T cell

Drugs targeting activated T cells typically function by inhibiting intracellular signaling pathways essential for activation (e.g., calcineurin inhibition by cyclosporine), blocking high-affinity growth factor receptors (e.g., IL-2 receptor antagonism by basiliximab), or interfering with necessary co-stimulatory signals required for full effector function (e.g., CTLA-4 Ig fusion proteins like abatacept) (StatPearls, 2023; NIH, 2022).